(Q43227919)

16 November 2017

title

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure (English)

1 reference

16 November 2017

1 reference

1 reference

Li-Jie Sun

1

1 reference

16 November 2017

Jian-Wu Yu

2

1 reference

16 November 2017

Yong-Hua Zhao

3

1 reference

16 November 2017

Peng Kang

4

1 reference

16 November 2017

Shu-Chen Li

5

1 reference

16 November 2017

publication date

24 November 2009

1 reference

Journal of Gastroenterology and Hepatology

16 November 2017

published in

1 reference

16 November 2017

volume

25

1 reference

16 November 2017

issue

3

1 reference

16 November 2017

page(s)

583-590

1 reference

Advances in critical care hepatology

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

AASLD position paper: the management of acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Management of decompensated HBV cirrhosis: lamivudine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Management of hepatitis B: summary of a clinical research workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Lamivudine treatment for acute severe hepatitis B: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06089.X

10.1111/J.1440-1746.2009.06089.X

21 January 2018

Identifiers

DOI

1 reference

16 November 2017

1 reference